Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 190 Cr.
- Current Price ₹ 180
- High / Low ₹ 184 / 135
- Stock P/E 35.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 19.7 %
- ROE 44.7 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 30.04 | 66.89 | 80.16 | 97.52 | |
| 24.21 | 59.75 | 68.21 | 82.40 | |
| Operating Profit | 5.83 | 7.14 | 11.95 | 15.12 |
| OPM % | 19.41% | 10.67% | 14.91% | 15.50% |
| 0.12 | 0.21 | 0.10 | 0.19 | |
| Interest | 1.58 | 2.34 | 2.97 | 3.66 |
| Depreciation | 3.79 | 3.93 | 3.97 | 4.58 |
| Profit before tax | 0.58 | 1.08 | 5.11 | 7.07 |
| Tax % | 56.90% | 38.89% | 25.44% | 24.33% |
| 0.25 | 0.67 | 3.81 | 5.35 | |
| EPS in Rs | 0.62 | 1.68 | 5.01 | 6.93 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 178% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| Last Year: | 45% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 7.60 | |
| Reserves | 3.49 | 4.16 | 4.38 | |
| 29.53 | 35.99 | 42.39 | ||
| 15.89 | 20.13 | 26.52 | ||
| Total Liabilities | 52.91 | 64.28 | 80.89 | |
| 21.39 | 20.75 | 21.93 | ||
| CWIP | 0.00 | 0.00 | 2.10 | |
| Investments | 0.00 | 0.00 | 0.00 | |
| 31.52 | 43.53 | 56.86 | ||
| Total Assets | 52.91 | 64.28 | 80.89 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -4.93 | -1.05 | 4.05 | 9.25 | |
| -3.31 | -3.08 | -7.18 | -11.14 | |
| 8.17 | 4.14 | 3.45 | 1.62 | |
| Net Cash Flow | -0.07 | 0.01 | 0.32 | -0.27 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 234.63 | 104.11 | 115.79 | |
| Inventory Days | 136.35 | 121.40 | 160.81 | |
| Days Payable | 273.08 | 128.11 | 148.90 | |
| Cash Conversion Cycle | 97.89 | 97.41 | 127.70 | |
| Working Capital Days | 191.49 | 125.56 | 129.77 | |
| ROCE % | 8.01% | 16.40% |
Documents
Announcements
- Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th July, 2025 - Approval Of Audited Financial Results, Resignation Of Company Secretary, Change Of RTA, Appointment Of Auditors, And Other Matters 11 Jul
-
Board Meeting Intimation for Audited Financial Results Of The Company For The Financial Year Ended 31St March, 2025.
4 Jul - Board meeting on July 11 to approve FY25 results, CS resignation, change RTA, appoint auditors, approve related party transactions.
-
Compliances-Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations, 2018
4 Jul - Certificate confirming securities dematerialization details filed for quarter ended June 30, 2025.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Jun
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 16 Jun
Annual reports
No data available.
Business Verticals[1]
a) Own brands: ** Its own brand include "Glow Up" (cosmetics) and "Regero" (pharmaceuticals).
b) Contract Manufacturing**: It also engages in contract manufacturing for domestic and international clients, serving markets like the USA, Bolivia, Guatemala, Botswana, Iraq, and Yemen.